Trial Profile

Efficacy of Leptin Replacement in Treatment of Lipodystrophy

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 04 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Metreleptin (Primary)
Indications Congenital generalised lipodystrophy
Focus Therapeutic Use

Most Recent Events

05 Jul 2021 Results published in the Journal of Clinical Endocrinology and Metabolism
20 May 2021 Results estimating the treatment effect of metreleptin compared to BSC on the metabolic complications of lipodystrophy in generalised lipodystrophy or partial lipodystrophy patients presented at the 26th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
02 Apr 2021 Results of a matched cohort analysis (of data from 3 studies NCT00025883, NCT01778556 and NCT00005905) assessing the effect of Leptin therapy on survival in generalized and partial Lipodystroph published in the Journal of Clinical Endocrinology and Metabolism

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com